CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on February 25, 2021
BENITEC BIOPHARMA INC.
3940 Trust Way
Hayward, California 94545
February 25, 2021
VIA EDGAR
Ada D. Sarmento
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-1004
| Re: | Benitec Biopharma Inc. |
Registration Statement on Form S-3 (File No. 333-253259)
Dear Ms. Sarmento:
Pursuant to Rule 461 of the Securities Act of 1933, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-253259), so that it may become effective at 4:00 p.m. Eastern Time on February 26, 2021, or as soon thereafter as practicable.
[Signature page follows]
| Very truly yours, | ||
| BENITEC BIOPHARMA INC. | ||
| By: | /s/ Dr. Jerel Banks | |
| Name: Dr. Jerel Banks | ||
| Title: Chief Executive Officer | ||
[Signature Page to Acceleration Request]